Astragaloside IV as a promising therapeutic agent for liver diseases: current landscape and future perspectives
Frontiers in Pharmacology · 23.04.2025 · 16
DOI: 10.3389/fphar.2025.1574154 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 23.04.2025. Verfasst von Chunyan Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Clinical Medical, Chengdu Medical College, Chengdu, China. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 164 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Astragaloside IV (C 41 H 68 O 14 , AS-IV) is a naturally occurring saponin isolated from the root of Astragalus membranaceus , a widely used traditional Chinese botanical drug in medicine. In recent years, AS-IV has attracted considerable attention for its hepatoprotective properties, which are attributed to its low toxicity as well as its anti-inflammatory, antioxidant and antitumour effects. Numerous preclinical studies have demonstrated its potential in the prevention and treatment of various liver diseases, including multifactorial liver injury, metabolic-associated fatty liver disease, liver fibrosis and liver cancer. Given the promising hepatoprotective potential of AS-IV and the growing interest in its research, this review provides a comprehensive summary of the current state of research on the hepatoprotective effects of AS-IV, based on literature available in databases such as CNKI, PubMed, ScienceDirect, Google Scholar and Web of Science. The hepatoprotective mechanisms of AS-IV are multifaceted, encompassing the inhibition of inflammatory responses, reduction of oxidative stress, improvement of insulin and leptin resistance, modulation of the gut microbiota, suppression of hepatocellular carcinoma cell proliferation and induction of tumour cell apoptosis. Notably, key molecular pathways involved in these effects include Nrf2/HO-1, NF-κB, NLRP3/Caspase-1, JNK/c-Jun/AP-1, PPARα/FSP1 and Akt/GSK-3β/β-catenin. Toxicity studies indicate that AS-IV has a high level of safety. In addition, this review discusses the sources, physicochemical properties, and current challenges in the development and clinical application of AS-IV, providing valuable insights into its potential as a hepatoprotective agent in the pharmaceutical and nutraceutical industries.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Clinical Medical, Chengdu Medical College, Chengdu, China.
- Department of Pharmacy, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
- Department of Otolaryngology-Head and Neck Surgery, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
- Department of Orthopedics, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
- Department of Pediatrics, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
- Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
Zitieren
APA
Chen, C., Bu, X., Deng, L., Xia, J., Wang, X., Chen, L., Li, W., Huang, J., Chen, Q., & Wang, C. (2025). Astragaloside IV as a promising therapeutic agent for liver diseases: current landscape and future perspectives. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1574154
Vancouver
Chen C, Bu X, Deng L, Xia J, Wang X, Chen L, et al. Astragaloside IV as a promising therapeutic agent for liver diseases: current landscape and future perspectives. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1574154
BibTeX
@article{Chen2025,
author = {Chen, Chunyan and Bu, Xiaolan and Deng, Liping and Xia, Jiayan and Wang, Xinming and Chen, Li and Li, Wen and Huang, Jie and Chen, Qixiang and Wang, Cheng},
title = {Astragaloside IV as a promising therapeutic agent for liver diseases: current landscape and future perspectives},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1574154}
}
EUVIMED